NLS Pharmaceutics (NLSP) announced that it intends to effect a reverse share split of the company’s issued and outstanding common shares, par value CHF 0.03 per share, at a ratio of 1-for-10. The company’s common shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on October 31, under the new trading symbol (NCEL), and new name, NewcelX, following the anticipated closing of the merger with Kadimastem.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NLSP:
- NLS Pharmaceutics and Kadimastem Finalize Merger Conditions
- NLS Pharmaceutics Announces Strategic Collaboration for Gene-Edited Cell Therapies
- NLS Pharmaceutics partner Kadimastem to collaborate with TargetGene
- NLS Pharmaceutics and Kadimastem Secure Nasdaq Approval for Merger
- NLS Pharmaceutics receives Nasdaq approval for listing